5-氯苯并[b]噻吩-3-乙酰氯 | 100068-26-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 5-氯苯并[b]噻吩-3-乙酰氯
• 英文名称: 5-chlorobenzothiophene-3-acetyl chloride
• 英文别名: 2-(5-chloro-1-benzothiophene-3-yl)acetic acid；5-chloro-benzo[b]thiophene-3-acetic acid chloride；2-(5-Chloro-1-benzothiophen-3-yl)acetyl chloride
• CAS: 100068-26-6
• 化学式: C₁₀H₆Cl₂OS
• 分子量: 245.129
• InChiKey: XNZQBVWFCMCDKN-UHFFFAOYSA-N

物化性质

• 沸点：
  368.5±32.0 °C(Predicted)
• 密度：
  1.473±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-氯苯并[b]噻吩-3-乙酰氯 在 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 丙酮 为溶剂， 生成 3-(5-chlorobenzo[b]thiophen-3-yl)-2-oxopropyl acetate
  参考文献：
  名称：

  2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic Acid (PSI-697):  Identification of a Clinical Candidate from the Quinoline Salicylic Acid Series of P-Selectin Antagonists

  摘要：

  P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events.

  DOI：

  10.1021/jm060631p
• 作为产物：
  描述：

  5-氯苯并噻酚-3-乙酸 在 N,N-二甲基甲酰胺 草酰氯 作用下， 以 四氢呋喃 为溶剂， 生成 5-氯苯并[b]噻吩-3-乙酰氯
  参考文献：
  名称：

  Methods and compositions for selectin inhibition

  摘要：

  本发明涉及抗炎物质领域，更特别地涉及作为哺乳动物粘附蛋白拮抗剂的新化合物。在某些实施例中，提供了治疗选择素介导疾病的方法，包括给予式I的化合物： 其中组分变量在此定义。

  公开号：

  US20050101569A1

文献信息

• Methods and Compositions for Treatment of Scleritis and Related Disorders
  申请人：Bedard Patricia W.

  公开号：US20080125454A1

  公开（公告）日：2008-05-29

  The present teachings relate to the field of anti-inflammatory substances and more particularly to compounds that are useful for the treatment of scleritis, a scleritis symptom, or a scleritis-related disorder. In one aspect, methods of treating scleritis, a scleritis symptom, or a scleritis-related disorder generally include administering to a subject a compound of Formula I: or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein W 1 , W 2 , R 1 , L, X, Y, Z, and n 1 are defined as described herein.

  目前的教导涉及抗炎物质领域，更具体地涉及对用于治疗巩膜炎、巩膜炎症状或与巩膜炎相关疾病有用的化合物。在一个方面，治疗巩膜炎、巩膜炎症状或巩膜炎相关疾病的方法通常包括向受试者施用公式I的化合物： 或其药用可接受的盐、水合物或酯，其中W 1 ，W 2 ，R 1 ，L，X，Y，Z和n 1 的定义如本文所述。
• [EN] AMIDE SUBSTITUTED THIAZOLES AS PROTEIN SECRETION INHIBITORS<br/>[FR] THIAZOLES À SUBSTITUTION AMIDE UTILISÉS EN TANT QU'INHIBITEURS DE LA SÉCRÉTINE PROTÉIQUE
  申请人：KEZAR LIFE SCIENCES

  公开号：WO2019046668A1

  公开（公告）日：2019-03-07

  Provided herein are thiazole carboxamide protein secretin inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I): and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.

  本文提供了噻唑羧酰胺蛋白质分泌抑制剂，例如Sec61的抑制剂，其制备方法，相关的药物组合物，以及使用这些物质的方法。例如，本文提供了化合物的公式（I）：及其药用盐和包含这些化合物的组合物。本文披露的化合物可以用于治疗炎症和/或癌症等疾病。
• Piperazines as P2X7 antagonists
  申请人：Betschmann Patrick

  公开号：US20080076924A1

  公开（公告）日：2008-03-27

  Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

  化合物I式的新型化合物或其药学上可接受的盐、代谢物、异构体、对映体或前药，其中取代基如本文所定义，这些化合物可用作治疗剂。
• Methods and Compositions for Selectin Inhibition
  申请人：Kaila Neelu

  公开号：US20090069564A1

  公开（公告）日：2009-03-12

  The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, methods for treating selectin mediated disorders are provided which include administration of compound of Formula I: wherein the constituent variables are defined herein.

  本发明涉及抗炎物质领域，更具体地涉及一种新型化合物，其作为哺乳动物粘附蛋白选择素的拮抗剂。在某些实施例中，提供了治疗选择素介导疾病的方法，其中包括给予式I化合物的治疗，其中该式中的组分变量在此定义。
• Aminomethylpiperazines as selective urotensin antagonists
  作者：Mark A. Hilfiker、Daohua Zhang、Sarah E. Dowdell、Krista B. Goodman、John J. McAtee、Jason W. Dodson、Andrew Q. Viet、Gren Z. Wang、Clark A. Sehon、David J. Behm、Zining Wu、Luz H. Carballo、Stephen A. Douglas、Michael J. Neeb

  DOI：10.1016/j.bmcl.2008.07.067

  日期：2008.8

  Aminomethylpiperazines, reported previously as being kappa-opioid receptor agonists, were identified as lead compounds in the development of selective urotensin receptor antagonists. Optimized substitution of the piperazine moiety has provided high affinity urotensin receptor antagonists with greater than 100-fold selectivity over the kappa-Opioid receptor. Select compounds were found to inhibit urotensin-induced vasoconstriction in isolated rat aortic rings consistent with the hypothesis that an urotensin antagonist may be useful for the treatment of hypertension. (c) 2008 Elsevier Ltd. All rights reserved.